375 related articles for article (PubMed ID: 18594135)
1. Von Willebrand factor-specific antibodies developing upon treatment of FVIII-deficient mice with different FVIII preparations.
Kallas A; Kuuse S; Maimets T; Pooga M
Acta Haematol; 2008; 119(4):244-7. PubMed ID: 18594135
[No Abstract] [Full Text] [Related]
2. von Willebrand factor and transforming growth factor-beta modulate immune response against coagulation factor VIII in FVIII-deficient mice.
Kallas A; Kuuse S; Maimets T; Pooga M
Thromb Res; 2007; 120(6):911-9. PubMed ID: 17376515
[TBL] [Abstract][Full Text] [Related]
3. Immune tolerance induction with a factor VIII concentrate containing von Willebrand factor (Haemoctin SDH®) in 14 patients with severe haemophilia A.
Bidlingmaier C; Kurnik K; Escuriola-Ettingshausen C; Jager R; Klamroth R; Male C; Marosi A; Nemes L; von Stackelberg A; Kreuz W
Haemophilia; 2011 Sep; 17(5):e837-40. PubMed ID: 21649797
[No Abstract] [Full Text] [Related]
4. Comparison of the immunogenicity of different therapeutic preparations of human factor VIII in the murine model of hemophilia A.
Delignat S; Dasgupta S; André S; Navarrete AM; Kaveri SV; Bayry J; André MH; Chtourou S; Tellier Z; Lacroix-Desmazes S
Haematologica; 2007 Oct; 92(10):1423-6. PubMed ID: 18024377
[TBL] [Abstract][Full Text] [Related]
5. Inhibitors in haemophilia A: the role of VWF/FVIII concentrates--a meeting report.
Kaveri S; Gringeri A; Heisel-Kurth M; Kreuz W
Haemophilia; 2009 Mar; 15(2):587-91. PubMed ID: 19347997
[No Abstract] [Full Text] [Related]
6. Management of bleeding disorders: basic science.
Ofosu FA; Santagostino E; Grancha S; Marco P
Haemophilia; 2012 May; 18 Suppl 2():8-14. PubMed ID: 22530574
[TBL] [Abstract][Full Text] [Related]
7. Adult haemophilia A patients with inhibitors: successful immune tolerance induction with a single FVIII/VWF product.
Rangarajan S; Jiménez-Yuste V; Santagostino E
Haemophilia; 2014 Nov; 20(6):e414-7. PubMed ID: 25333452
[No Abstract] [Full Text] [Related]
8. Novel therapies for immune tolerance in haemophilia A.
Collins PW
Haemophilia; 2006 Dec; 12 Suppl 6():94-100; discussion 100-1. PubMed ID: 17123401
[TBL] [Abstract][Full Text] [Related]
9. Immune tolerance induction with high von Willebrand factor/factor VIII content ratio concentrate in children with haemophilia A and high-responding inhibitor.
Platokouki H; Pergantou H; Xafaki P; Komitopoulou A; Aronis S
Haemophilia; 2009 Mar; 15(2):617-9. PubMed ID: 19175417
[No Abstract] [Full Text] [Related]
10. Inhibitor development.
Astermark J; Lacroix-Desmazes S; Reding MT
Haemophilia; 2008 Jul; 14 Suppl 3():36-42. PubMed ID: 18510520
[TBL] [Abstract][Full Text] [Related]
11. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
[TBL] [Abstract][Full Text] [Related]
12. Von Willebrand factor modulates factor VIII immunogenicity: comparative study of different factor VIII concentrates in a haemophilia A mouse model.
Behrmann M; Pasi J; Saint-Remy JM; Kotitschke R; Kloft M
Thromb Haemost; 2002 Aug; 88(2):221-9. PubMed ID: 12195693
[TBL] [Abstract][Full Text] [Related]
13. In vitro reactivity of factor VIII inhibitors with von Willebrand factor in different commercial factor VIII concentrates.
Tagariello G; Zanotto D; Radossi P; Sartori R; Belvini D; Salviato R
Am J Hematol; 2007 Jun; 82(6):460-2. PubMed ID: 17211843
[TBL] [Abstract][Full Text] [Related]
14. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
Reipert BM; van Helden PM; Schwarz HP; Hausl C
Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
[TBL] [Abstract][Full Text] [Related]
15. The role of VWF in the immunogenicity of FVIII.
Lacroix-Desmazes S; Repessé Y; Kaveri SV; Dasgupta S
Thromb Res; 2008; 122 Suppl 2():S3-6. PubMed ID: 18549909
[TBL] [Abstract][Full Text] [Related]
16. Factor VIII inhibitors: a 50-year perspective.
Green D
Haemophilia; 2011 Nov; 17(6):831-8. PubMed ID: 21592257
[TBL] [Abstract][Full Text] [Related]
17. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
Greninger DA; Saint-Remy JM; Jacquemin M; Benhida A; DiMichele DM
Haemophilia; 2008 Mar; 14(2):295-302. PubMed ID: 18081826
[TBL] [Abstract][Full Text] [Related]
18. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
Auerswald G; Spranger T; Brackmann HH
Haematologica; 2003 Jun; 88(6):EREP05. PubMed ID: 12826531
[TBL] [Abstract][Full Text] [Related]
19. Successful immune tolerance induction with factor VIII/von Willebrand factor concentrate in an elderly patient with severe haemophilia A and a high responder inhibitor.
Rivolta GF; Di Perna C; Franchini M; Riccardi F; Ippolito L; Lombardi M; Tagliaferri A
Blood Transfus; 2010 Jan; 8(1):66-8. PubMed ID: 20104281
[No Abstract] [Full Text] [Related]
20. Clinical overview of Fanhdi/Alphanate (plasma-derived, VWF-containing FVIII concentrate) in immune tolerance induction in haemophilia A patients with inhibitors.
Jiménez-Yuste V; Oldenburg J; Rangarajan S; Kurth MH; Bozzo J; Santagostino E
Haemophilia; 2016 Jan; 22(1):e71-4. PubMed ID: 26612826
[No Abstract] [Full Text] [Related]
[Next] [New Search]
